A bone marrow transplant replaces damaged or destroyed bone marrow with healthy blood-forming stem cells. It’s used to treat serious blood cancers like leukemia and lymphoma, as well as genetic blood disorders and immune system conditions. The procedure itself is less like surgery and more like a blood transfusion, but the preparation, recovery, and risks make it one of the most intensive treatments in modern medicine.
Why Bone Marrow Transplants Are Done
Bone marrow is the spongy tissue inside your bones that produces red blood cells, white blood cells, and platelets. When disease damages this factory, or when aggressive cancer treatment destroys it, a transplant can essentially rebuild it from scratch.
The most common reasons for a bone marrow transplant include leukemia, lymphoma, aplastic anemia (where the marrow stops making enough red blood cells), and inherited conditions like thalassemia. Some patients need a transplant not because their marrow is diseased, but because the chemotherapy or radiation needed to cure their cancer would permanently destroy their marrow as a side effect. In those cases, the transplant restores what the treatment took away. Certain immune system disorders, such as severe combined immunodeficiency syndrome, are also treated this way.
Autologous vs. Allogeneic Transplants
There are two main types, and the difference comes down to where the stem cells come from.
An autologous transplant uses your own stem cells. Before you undergo high-dose treatment, doctors collect stem cells from your blood through a filtering process called apheresis, freeze them, and return them to your body afterward. Because the cells are yours, your immune system won’t reject them. This type is common for certain lymphomas and myelomas.
An allogeneic transplant uses stem cells from a donor. This is necessary when the disease itself originates in the bone marrow, since using your own cells could reintroduce the problem. Allogeneic transplants carry more risk, particularly a complication called graft-versus-host disease, but they also bring a powerful benefit: the donor’s immune cells can recognize and attack any remaining cancer cells in your body.
How Donor Matching Works
For an allogeneic transplant, finding the right donor is critical. Doctors match patients and donors based on proteins called HLA markers. Your body has 12 unique HLA markers, and the millions of possible combinations mean that finding a full match (where all markers align) can be difficult. Siblings have roughly a 25% chance of being a full match. When no sibling match exists, doctors search registries of volunteer donors worldwide.
A haploidentical (or “haplo”) match is a newer option where the donor shares only half of the patient’s HLA markers. This is significant because a parent, child, or half-matched sibling can serve as a donor, dramatically expanding the pool of candidates. Research from Cleveland Clinic found that graft failure rates were virtually identical between haplo-matched and fully matched unrelated donors when both groups received the same post-transplant medication. Two-year overall survival was lower for the haplo group (56% vs. 69%), but factors like disease severity and patient health played a large role in that gap, and outcomes continue to improve as techniques are refined.
Preparing for the Transplant: Conditioning
Before new stem cells can be infused, your body needs to be prepared through a process called conditioning. This typically involves several days of high-dose chemotherapy, sometimes combined with radiation. Conditioning serves three purposes at once: it suppresses your immune system so it won’t reject the incoming cells, it clears space in your bone marrow for the new stem cells to settle and grow, and it destroys any remaining cancer cells.
Conditioning is the hardest part of the process for most patients. Side effects are significant and can include severe nausea, fatigue, mouth sores, and a dramatically weakened immune system. You’ll be in the hospital for this phase, typically in a specialized unit designed to minimize infection risk.
The Transplant and Engraftment
The transplant itself is surprisingly undramatic. Stem cells are infused through a central line into your bloodstream, much like a blood transfusion. The procedure takes one to several hours, and you’re awake the entire time.
What happens next is the remarkable part. The transplanted stem cells travel through your bloodstream, find their way to the hollow spaces inside your bones, and begin producing new blood cells. This process, called engraftment, typically takes two to six weeks. During those weeks, your blood counts are dangerously low. You have almost no functioning immune system, minimal ability to clot, and too few red blood cells to carry oxygen efficiently. This period requires close monitoring, frequent blood transfusions, and strict infection precautions.
Doctors track engraftment by checking your blood counts daily. The first sign that new marrow is working is usually a rise in white blood cell counts. Once counts stabilize, it signals that the transplanted cells have taken hold.
Graft-Versus-Host Disease
The most significant complication unique to allogeneic transplants is graft-versus-host disease, or GVHD. It occurs when the donor’s immune cells (now living in your body) identify your tissues as foreign and attack them. GVHD doesn’t happen with autologous transplants because the cells are your own.
Acute GVHD can develop in the weeks and months after transplant. It most commonly affects the skin (causing rashes ranging from mild to severe), the digestive system (nausea, diarrhea, abdominal pain, loss of appetite), and the liver (yellowing of the skin, dark urine, swelling). Symptoms can be mild and manageable or severe and life-threatening.
Chronic GVHD is a longer-term condition that typically appears within the first year but can develop several years later. It behaves more like an autoimmune disease, affecting a wider range of organs. Symptoms may include thickened or itchy skin, dry and irritated eyes, mouth sores, joint stiffness, shortness of breath, and genital dryness or irritation. Some patients deal with chronic GVHD for years, requiring ongoing treatment to keep it controlled.
Interestingly, mild GVHD after a cancer-related transplant can actually be beneficial. The same immune response that attacks your tissues also attacks lingering cancer cells, a phenomenon called the graft-versus-tumor effect. Managing GVHD is about finding the balance between suppressing it enough to protect your organs while preserving enough immune activity to fight residual disease.
Recovery Timeline
Recovery from a bone marrow transplant is measured in months, not weeks. The first 30 days are focused on engraftment and surviving the period of dangerously low blood counts. Most patients remain hospitalized or in very close outpatient follow-up during this time. Infections are the biggest threat, and even a low-grade fever can require immediate intervention.
The 100-day mark is a traditional milestone in transplant medicine. By this point, the acute risks of graft failure and early GVHD have largely passed, and blood counts are usually stable. But “stable” doesn’t mean “recovered.” Your immune system is still profoundly immature, comparable in some ways to a newborn’s. You’ll likely still be on multiple medications, attending frequent clinic visits, and avoiding crowds and anyone who’s sick.
Full immune recovery takes one to two years for most patients. During this time, you’ll gradually be revaccinated (your pre-transplant immunity is wiped out by conditioning), restrictions on diet and activity will ease, and energy levels will slowly improve. Some people return to work or school within six months; others need a full year or longer. Fatigue is one of the most persistent complaints, often lasting well beyond the point when blood counts look normal on paper.
Other Risks and Side Effects
Beyond GVHD, bone marrow transplant patients face a range of potential complications. Infections are the most immediate danger, particularly bacterial and fungal infections during the weeks when white blood cell counts are at their lowest. Viral reactivations (where dormant viruses in your body flare up because the immune system can no longer keep them in check) are also common in the months after transplant.
Organ damage from the conditioning regimen can affect the heart, lungs, liver, and kidneys. Infertility is common, and patients who may want children are usually counseled about fertility preservation before treatment begins. Long-term survivors also face an elevated risk of secondary cancers, cataracts, and hormonal imbalances years after the transplant. These late effects make ongoing follow-up important even when someone feels fully recovered.
Graft failure, where the transplanted cells don’t engraft or stop working, is relatively uncommon but serious. It occurs in roughly 5 to 7% of cases depending on the type of transplant and may require a second transplant.